Differential antitumor activity of compounds targeting the ubiquitin-proteasome machinery in gastrointestinal stromal tumor (GIST) cells.

Furthermore, delanzomib led to a highly significant reduction of proliferation, which was equivalent to imatinib treatment (Fig. 5B ; reduction of the Ki-67-positive proliferation fraction from 26.8% in placebo-treated controls to 3.0% in delanzomib-treated tumors; decrease of phosphorylated histone H3 S10 positive mitotic cells from 88/10 HPF to 4/10 HPF).

also in 132,142 other papers